论文部分内容阅读
心房颤动(Atrial fibrillation,AF)是临床上最常见的心律失常,在普通人群中发病率约为0.4%,发病率随着年龄增长而增加[1]。我国现有约800万房颤患者,发生脑卒中的风险是非房颤患者的2~7倍,严重影响着患者的生活质量,其引起的卒中及脏器栓塞等严重并发症可导致患者残疾甚至死亡。目前药物治疗和导管射频消融是改善房颤患者预后最主要的治疗方法,但是药物治疗的有效率只有20%左右,
Atrial fibrillation (AF) is the most common clinical arrhythmia in the general population, the incidence rate of about 0.4%, the incidence increases with age [1]. About 8 million patients with AF in our country have a stroke risk of 2 to 7 times that of non-AF patients, which seriously affects their quality of life. Serious complications such as stroke and organ embolism can lead to disability and even patient disability death. The current drug treatment and catheter radiofrequency ablation is to improve the prognosis of patients with atrial fibrillation the most important treatment, but the effective rate of drug treatment is only about 20%